

## Breast Cancer Session Program Thursday, 20 October 2016 | 08:30 – 12:00 Al Ras 2

### Session 1: How should we do it in October 2016?

Chairpersons: Amit Agarwal, India | Zulqarnain Chaudhry, Pakistan

08:30 – 08:50 **Debate 1:** Mammographic Screening

If I was a Health Minister in Middle East or South Asia I will start Population level Mammographic Breast Cancer Screening

Chaitanyanand Koppiker, India

If I was a Health Minister I will actively Prevent Waste of Resources In Mammographic Breast Cancer Screening

Nagi S. El Saghir, Lebanon

08:50 – 09:10 Requesting germline mutation work-up in Patients with Breast Cancer: Current Indications, Techniques and Interpretation

Hamdy Abdel Azim, Egypt

09:10 – 09:20 Liquid Biopsies in Metastatic Breast Cancer: We have blood on our Hands

Stephen Johnston, UK

09:20 – 09:30 Weight control and exercise should be an integral part of EBC Management: Evidence and Practical Recommendations

Bhawna Sirohi, UK

### Session 2: State-of-Science in Loco-Regional Therapy: 2016

Chairpersons: Sanjay Sharma, India | Amina Khan, Pakistan

09:30 – 09:55 **Panel Discussion 1:** Controversial Issues in Surgical Management of Breast Cancer

**Moderator:** Nita Nair, India

**Panelists:** Nagi S. El Saghir, Lebanon | Annett Al-Hamadi, UAE | Anita Ramesh, India  
Salim Chaib-Rassou, UAE | Falah Al Khatib, UAE | Aysegul Sahin, USA  
Dalia Mahmoud Elshourbagy, UAE

**Moderator to Discuss:**

- Post-NACT SNB
- Skin Sparing Mastectomy
- Immediate vs Delayed Breast Reconstruction
- Surgery of Primary in Stage 4 Disease (Turkish trial ASCO 2016, Indian trial Lancet Oncol 2015, Metaanalysis 2016)
- Omitting Surgery in Exceptional Responders to NACT (Recent Review Article with Data, Prediction of Exceptional Response to NACT without Resorting to Surgery)



09:55 – 10:20 **Panel Discussion 2: Controversial Issues in Radiation Therapy**  
**Moderator:** Nadia Malik, UAE  
**Panelists:** Syed Mansoor Hasnain, UAE | | Salim Chaib-Rassou, UAE  
Tanweer Shahid, India | Tanuja Shet, India | Sanjay Sharma, India | Falah Al Khatib, UAE  
Alexandra Economacos, UAE

**Moderator to Discuss:**

- Hypo fractionation (START trials, 5-day fractionation, others) for all patients, for some only, safety issues, technical requirements
- Regional nodal radiation including whether RT can replace axillary surgery
- APBI including brachy, mammosite, intra-op RT, other techniques. Which would be ideal patients?
- Is it possible to personalize RT in breast cancer – by age, intrinsic subtypes, proliferation status, signatures of radio-resistance, others

10:20 – 10:30 Coffee Break

10:30 – 11:00 **Opening Ceremony**

**Session 3: Navigating the Maze of Systemic Therapy**

**Chairpersons:** Salim Chaib-Rassou, UAE | Nagi S. El Saghir, Lebanon

10:30 – 10:50 **Debate 2:**

Anthracyclines are indispensable in almost all patients Needing Adjuvant chemotherapy Maroun El Khoury, UAE

Anthracyclines can and should be omitted from adjuvant chemotherapy Regimens of many patients Neelam Siddique, Pakistan

10:50 – 11:05 Extended adjuvant endocrine Therapy: Evidence and Patient Selection Stephen Johnston, UK

11:05 – 11:30 **Panel Discussion 3: ER positive MBC: Spoilt for Choice**

**Moderator:** Vineet Gupta, India

**Panelists:** Bhawna Sirohi, UK | Shona Nag, India | Neelam Siddique, Pakistan  
Dhairyasheel Savant, India | Amit Agarwal, India | Sudeep Gupta, India  
Peter Schmid, UK | Stephen Johnston, UK | Falah Al Khatib, UAE

**Moderator to Discuss:**

- Patient selection for fulvestrant with or without AI
- Patient selection for CDK 4/6 inhibitors
- Patient selection for everolimus

11:30 – 11:50 Recent Advances in Management of ER Positive Advanced Breast Cancer: Mohsen Mokhtar, Egypt

11:50 – 12:00 Q & A

